Molecular and Translational Medicine10.1007/978-3-319-55825-7_102017141-154Patient-Derived Xenografts as Cancer Models for Preclinical Drug ScreeningJuliet A. Williams
Patient Derived Tumor Xenograft Models10.1016/b978-0-12-804010-2.00017-52017229-241Patient-Derived Xenograft Model of Pancreatic CancerM.V. Rios Perez, J.B. Fleming,
Patient Derived Tumor Xenograft Models10.1016/b978-0-12-804010-2.00019-92017257-271Patient-Derived Xenograft Models of Ovarian/Gynecologic TumorsL. Liang, I. Mercado-Uribe, N. Niu, Y. Jiang, W. Cheng, J. Zhang, G.B. Mills, C. Scott, A.K. Sood, J. Liu,
European Journal of Cancer Supplements10.1016/s1359-6349(04)80022-3200428813 Patient and cell line derived human tumor xenograft models — preclinical/clinical correlationsH.H. Fiebig,
Patient Derived Tumor Xenograft Models10.1016/b978-0-12-804010-2.00003-5201725-36Challenges and Limitations of Mouse Xenograft Models of CancerB.W. Simons, C. Brayton,
European Journal of Cancer10.1016/s0959-8049(17)30399-4201772S96A preclinical evaluation of niraparib efficacy as monotherapy, maintenance and after olaparib treatment (PARP inhibitor after PARP inhibitor) in patient-derived ovarian xenograft tumor modelsK. Mikule, S. Wang, S.J. Weroha, J. Nakashima, K. Wilcoxen,
Ovarian Cancer10.1007/978-1-0716-1956-8_172021255-274Humanized Patient-Derived Xenograft Models of Ovarian CancerSarah B. Gitto, Erin George, Sergey Medvedev, Fiona Simpkins, Daniel J. Powell
Patient Derived Tumor Xenograft Models10.1016/b978-0-12-804010-2.00002-3201715-23History of Mouse Cancer ModelsL.R. Hill, P.T. Tinkey,
Patient-Derived Mouse Models of Cancer10.1007/978-3-319-57424-0_3201713-41Patient-Derived Xenograft Models for Human Cancer: The Freiburg ExperienceHeinz-Herbert Fiebig
Patient Derived Tumor Xenograft Models10.1016/b978-0-12-804010-2.00016-32017217-228Patient-Derived Xenograft Models of Prostate TumorsP.J. Russell, E.D. Williams, R. Taylor, M.G. Lawrence, G. Risbridger,